Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bufylline is a theophylline derivative and a member of the xanthine class, used primarily as a bronchodilator for the treatment of asthma and other obstructive airway diseases. It acts by relaxing smooth muscle in the airways, thereby improving airflow and reducing bronchospasm. Bufylline is classified as an anti-asthmatic agent, bronchodilator, and vasodilator. Its mechanism of action involves antagonism at adenosine receptor A1, which leads to relaxation of bronchial smooth muscle. Like other xanthines, it may also have mild stimulant effects on the central nervous system and cardiovascular system. Bufylline is typically indicated for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bufylline.